Cite
HARVARD Citation
Lythgoe, H. et al. (2018). Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology. pp. 398-401. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lythgoe, H. et al. (2018). Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology. pp. 398-401. [Online].